CardioWise Inc. news
An internationally recognized entrepreneur, Mr. Breukelman is a pioneer in imaging technology, initially as principal and chairman of IMAX Corporation, followed by significant transformative contributions to medical and scientific research companies in information technology and strategic development.
Jack Coats, Chief Executive Officer of CardioWise, Inc., announced that Mr. William A. Breukelman has been named to the company’s Board of Directors. CardioWise, Inc. has recently
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the European Union (EU) that will allow CardioWise to market its products there.
This follows the com
CardioWise® and Lucem Health™ announced that CardioWise has become a founding member of the Lucem Health Innovation Collaborative, a partner program designed to help AI/ML innovation move to the forefront of healthcare. The collaborative launched by Mayo Clinic along with other investing partners will help digital health innovators create, deploy, and commercialize transformational solutions powered by artificial intelligence and machine learning models.
Clinically focused A
The University of California San Francisco (UCSF) Health Awards named CardioWise, Inc. as a Rising Star in the Clinical Diagnostic Tool category. The awards highlight the health tech industry, showcasing the best new products and technologies in digital health and life sciences.
The University of California San Francisco (UCSF) Health Hub has selected CardioWise, Inc. a Digital Health Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. The goal of UCSF Digital Health Awards was to select companies that promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital stays, reduced patient and insurer costs, faster cures, and happier doctors and patients. The awards are intended to showcase n
CardioWise, Inc., is pleased to announce two significant patents protecting its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). The European Union Patent Number 12839978.9 was awarded on February 2, 2019, followed closely by the U.S. Patent on June 7, 2019 (patent application number 14/350,991). Both patents are entitled “Methods for Evaluating Regional Cardiac Function and Dyssynchrony from a Dynamic Imaging Modality using Endocardial Motio
CardioWise, Inc., is pleased to announce that the company has acquired the worldwide rights to Image Toolbox heart functional analysis software, and pending patent from Johns Hopkins Technology Ventures through a license agreement. The US Patent application was filed November 11, 2016. The software uses cardiac CT patient data sets to determine which heart failure patients may benefit from implantation of a Cardiac Resynchronization Therapy device and can guide the placement of leads to ensur
CardioWise, Inc. has completed National Science Foundation (NSF) Phase I and IB Small Business Innovation and Research (SBIR) grants that continued the development and commercialization of a non-invasive analysis method for detection of heart disease. The final report submitted to the NSF in December detailed the research and development milestones that were achieved during the 2013 award period including:
- Development and testing of cloud-based software as a service (SaaS) solu
CardioWise, Inc. has received a National Science Foundation (NSF) Phase IB Small Business Innovation Research grant of $30,000 to continue the development and commercialization of a non-invasive analysis method for detection of heart disease. This award follows and builds on the successful achievement of milestones in a Phase I grant of $150,000 received by the company in January.
The Phase IB award is a supplement that can be granted if the recipient has demonstrated to the NSF that